Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 5;120(24):e2216612120. doi: 10.1073/pnas.2216612120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

PMC Copyright notice

Fig. 4. — Neutralization of PSV variants by bsNb₄-Igs. (A) Neutralization of SARS-CoV-2 PSVs by LM18-based bsNb₄-Igs, LM18-Nb₄-Ig, and Nb-C2/Nb-C4 bsNb₄-Igs. IC₅₀ values of clinical antibody candidates (LY-CoV16, REGN10933, and REGN-10987), CC12.1, and CC6.30 from our previous study (35) were added for reference. (B) Neutralization of omicron PSV by LM18- or Nb-C2-136-based bsNb₄Igs. Omicron escaped from the clinical antibody candidates LY-CoV555, REGN-10933, and REGN-10987 and the monoclonal antibodies CC12.1 and CC6.30 (36). (C) Comparison between bsNb₄-Ig and the corresponding Fabs, with IC₅₀ as molar concentration. The black and purple dotted lines indicate the absence of neutralization (≥100 µg/mL) and the IC₅₀ value of LM18-Fc, respectively. (D) Neutralization of Wuhan-1 SARS-CoV-2 PSV by LM18-based and affinity-matured LM18-based bsNb₄-Igs.